Peres Jepchirchir Suspended for EPO: Sample Taken Before Sydney Marathon, AIU Issues Provisional Ban

At the 30 August 2026 edition of the Sydney Marathon, a timing board listing five-year-old Tokyo benchmarks in one column and the day's expected splits in another stood near the finish area as Peres Jepchirchir crossed the line. Two hours, 18 minutes and 31 seconds — a mark no analyst had previously filed under her baseline — will now be written on a different sheet. Last week the Athletics Integrity Unit announced that the Tokyo 2026 Olympic champion and Budapest 2026 World Championships marathon winner has been provisionally suspended after an out-of-competition sample tested positive for EPO (erythropoietin). The sample was collected in Kenya before the Sydney race. The Sydney timing was a return to her foundation. Three weeks after the race, Kenyan media attention was on the bottom of the order list: compatriot Irene Chepet Cheptai finished more than three minutes behind. The question is not which race she won — she has won five different major classics in different years — but into which register the sample entry from that day will now be filed. EPO is a natural substance produced in the kidneys that stimulates red blood cell production; injected, it is detectable in urine or blood only for a short window. That detail matters because in any EPO case, the gap between 'when the sample was taken' and 'when the result came' becomes the key to interpreting an athlete's career record. This is a career I have watched grow on paper. In 2026 she set the women's half-marathon world record, then broke it three more times in 2026. The 2026 New York Marathon, 2026 Boston Marathon and 2026 London Marathon titles build a profile I file alongside figures like 86.47 and 87.58 from my junior ledger, so the sequence can be verified. Returning to Tokyo last year to win the World Championships — the same city where she won Olympic gold in 2026 — shows a continuity rare in marathon running. I always say: 'Every record has a trench layer; I start at the bottom.' Here the trench layer is the sample taken in Kenya before Sydney. Three dates — when the sample was taken, which laboratory received it, and when the result came — have not been disclosed. AIU has announced the provisional suspension but has not made public the exact collection date or the status of the B-sample test. 'The 90-metre mark is a hypothesis, not a headline' — the same applies to EPO here: 2:18:31 and the positive EPO result are two separate documents, and reading them in one sentence is the same mistake as the asterisk over the 2026 relay team. The Sydney Marathon was not just another title but part of a series that began as the seventh world major in 2026. It is a new institutional layer in the marathon landscape, creating a new competitive category between the established races. Winning it seemed a step forward in this cycle; three weeks later the same result now demands to be read by pairing one document with another. I went back to the 2026 sheet — I had filed an Indian young javelin thrower's progression as 'stable, not explosive' at the time. The same method applies here: her pre-Sydney sequence is the same as after London 2026. Whether that sequence is right or wrong is a separate matter, but without the sample timeline any conclusion is incomplete. I am not erasing records I have verified — the 2026 half-marathon world record and the three improvements after 2026, New York 2026, Boston 2026 and London 2026 — but I am also saying that every record has a date, and stamping a career without knowing whether the EPO stain came before or after that date is the same error as declaring a trend from a single meet. A provisional suspension does not mean the hearing is over. Under World Athletics rules, an athlete is kept from competition until disciplinary proceedings conclude, and the duration depends on sample collection, B-sample analysis and hearing dates. Here is the gap I cannot literally fill: AIU has clear rules, but timing varies by case. My job is not to score the procedure as if it were part of the AIU marathon programme; my job is to identify what procedure does not exist — such as the B-sample date. 'The archive had a gap where the data should have been' — this line applies directly. For Kenya the case reopens an old debate, but I must keep two doubts separate: one, the lack of information on EPO use, and two, institutional defensive reaction. These are different failures, and in both the athlete is the first casualty. The asterisk placed over the 2026 relay legacy after the 2026 CAS-confirmed bans is the same kind of mark. Yes, the asterisk will appear again, but from which date is not yet settled. When I open the file from the 2026 empty-track audit — where I reconstructed splits from a 25fps broadcast clip and found a 0.4-second discrepancy — I remember that time is reliable if its source is verified. The source for the EPO test is AIU, the same body that collects out-of-competition samples around marathons. If the B-sample also comes back positive, the suspension could exceed one year and cast doubt on the past four years of achievements. But for now only one fact is public: the sample was taken in Kenya before Sydney. 'Three centimetres is not a trend; it is a question' — here the question of 2:18:31 and the answer of EPO are filed in two different registers. I refuse to put them together until the B-sample and hearing dates are clear. In the three weeks since the Sydney Marathon, her name is still on the winners' list of that seventh major. Looking ahead, two dates will matter: the B-sample test date and the hearing date. The first will indicate whether the case proceeds; the second will indicate how long the suspension lasts. Until then, she has one option — to let 2:18:31 of her career stand in the record as I kept 86.47 on the 2026 sheet without distortion. But the EPO result will determine the context in which that 2:18:31 is read. Until the dates of both registers emerge, the discussion is incomplete.